Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Multiparametric MRI and radiomics in prostate cancer: a review.

Sun Y, Reynolds HM, Parameswaran B, Wraith D, Finnegan ME, Williams S, Haworth A.

Australas Phys Eng Sci Med. 2019 Mar;42(1):3-25. doi: 10.1007/s13246-019-00730-z. Epub 2019 Feb 14.

PMID:
30762223
2.

Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy.

Yang F, Ford JC, Dogan N, Padgett KR, Breto AL, Abramowitz MC, Dal Pra A, Pollack A, Stoyanova R.

Transl Androl Urol. 2018 Jun;7(3):445-458. doi: 10.21037/tau.2018.06.05. Review.

3.

Multiparametric (mp) MRI of prostate cancer.

Kumar V, Bora GS, Kumar R, Jagannathan NR.

Prog Nucl Magn Reson Spectrosc. 2018 Apr;105:23-40. doi: 10.1016/j.pnmrs.2018.01.001. Epub 2018 Jan 31. Review.

PMID:
29548365
4.

Prostate cancer radiomics and the promise of radiogenomics.

Stoyanova R, Takhar M, Tschudi Y, Ford JC, Solórzano G, Erho N, Balagurunathan Y, Punnen S, Davicioni E, Gillies RJ, Pollack A.

Transl Cancer Res. 2016 Aug;5(4):432-447.

5.

Radiomics based targeted radiotherapy planning (Rad-TRaP): a computational framework for prostate cancer treatment planning with MRI.

Shiradkar R, Podder TK, Algohary A, Viswanath S, Ellis RJ, Madabhushi A.

Radiat Oncol. 2016 Nov 10;11(1):148.

6.

Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer.

Gupta RT, Spilseth B, Patel N, Brown AF, Yu J.

Abdom Radiol (NY). 2016 May;41(5):831-43. doi: 10.1007/s00261-015-0579-5. Review.

PMID:
27193786
7.

Multiparametric MRI in detection and staging of prostate cancer.

Boesen L.

Dan Med J. 2017 Feb;64(2). pii: B5327. Review.

PMID:
28157066
8.

Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists.

Yoo S, Kim JK, Jeong IG.

Korean J Urol. 2015 Jul;56(7):487-97. doi: 10.4111/kju.2015.56.7.487. Epub 2015 Jun 30. Review.

9.

Latest Evidence on the Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Insignificant Prostate Cancer: A Systematic Review.

Cantiello F, Manno S, Russo GI, Cimino S, Privitera S, Morgia G, Cicione A, Damiano R.

Anticancer Agents Med Chem. 2018;18(7):925-930. doi: 10.2174/1871520618666180105105413.

PMID:
29303080
10.

Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.

Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A.

Eur Urol. 2015 Dec;68(6):1045-53. doi: 10.1016/j.eururo.2015.01.013. Epub 2015 Feb 2. Review.

PMID:
25656808
11.

Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer.

An JY, Sidana A, Choyke PL, Wood BJ, Pinto PA, Türkbey İB.

Balkan Med J. 2017 Sep 29;34(5):388-396. doi: 10.4274/balkanmedj.2017.0708.

12.

Magnetic resonance imaging in active surveillance-a modern approach.

Giganti F, Moore CM.

Transl Androl Urol. 2018 Feb;7(1):116-131. doi: 10.21037/tau.2017.12.23. Review.

13.

Objective risk stratification of prostate cancer using machine learning and radiomics applied to multiparametric magnetic resonance images.

Varghese B, Chen F, Hwang D, Palmer SL, De Castro Abreu AL, Ukimura O, Aron M, Aron M, Gill I, Duddalwar V, Pandey G.

Sci Rep. 2019 Feb 7;9(1):1570. doi: 10.1038/s41598-018-38381-x.

14.

Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making.

Duvnjak P, Schulman AA, Holtz JN, Huang J, Polascik TJ, Gupta RT.

Radiol Clin North Am. 2018 Mar;56(2):239-250. doi: 10.1016/j.rcl.2017.10.007. Epub 2017 Dec 11. Review.

PMID:
29420979
15.

[Multiparametric MRI. The role of MRI techniques in the diagnosis, staging and follow up of prostate cancer].

Vilanova JC, Luna-Alcalá A, Boada M, Barceló J.

Arch Esp Urol. 2015 Apr;68(3):316-33. Review. Spanish.

PMID:
25948803
16.

Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making.

Duvnjak P, Schulman AA, Holtz JN, Huang J, Polascik TJ, Gupta RT.

Urol Clin North Am. 2018 Aug;45(3):455-466. doi: 10.1016/j.ucl.2018.03.010. Review.

PMID:
30031465
17.

What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.

Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O.

Eur Urol. 2017 Aug;72(2):250-266. doi: 10.1016/j.eururo.2017.02.026. Epub 2017 Mar 21. Review.

PMID:
28336078
18.

Magnetic resonance imaging in prostate cancer detection and management: a systematic review.

Monni F, Fontanella P, Grasso A, Wiklund P, Ou YC, Randazzo M, Rocco B, Montanari E, Bianchi G.

Minerva Urol Nefrol. 2017 Dec;69(6):567-578. doi: 10.23736/S0393-2249.17.02819-3. Epub 2017 May 8. Review.

19.

The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel.

Muller BG, Fütterer JJ, Gupta RT, Katz A, Kirkham A, Kurhanewicz J, Moul JW, Pinto PA, Rastinehad AR, Robertson C, de la Rosette J, Sanchez-Salas R, Jones JS, Ukimura O, Verma S, Wijkstra H, Marberger M.

BJU Int. 2014 Feb;113(2):218-27. doi: 10.1111/bju.12243. Epub 2013 Nov 13.

20.

Multi-parametric magnetic resonance imaging as a management decision tool.

Johnson DC, Reiter RE.

Transl Androl Urol. 2017 Jun;6(3):472-482. doi: 10.21037/tau.2017.05.22. Review.

Supplemental Content

Support Center